2SEVENTY BIO INC
1 day chart
2seventy bio, Inc. is a cell and gene therapy company, which is focused on the research, development and commercialization of transformative treatments for cancer. The Company is advancing multiple clinical programs, including DARIC33, for the treatment of pediatric patients with relapsed and refractory acute myeloid leukemia, and bbT369, for the treatment of patients with B-cell non-Hodgkins lymphoma, as well as multiple preclinical programs, including bbT4015, an engineered chimeric antigen receptor (CAR) T cell therapy targeting MUC16. Additionally, together with its partner Bristol Myers Squibb (BMS), the Company is delivering ABECMA to multiple myeloma patients in the United States for the treatment of adults with multiple myeloma who have received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and a cyclic ADP ribose hydrolase (anti-CD38) monoclonal antibody.
Buy US stocks in Australia with $0 brokerage and trade TSVT today!
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.